Pancreas cancer represents 3.2% of all new cancer cases. Only 9.3% survive for more than 5 years. Pancreatic adenocarcinoma is the fourth most common cause of cancer-related death among U.S. men (after lung, prostate, and colorectal cancer) and women (after lung, breast, and colorectal cancer)
The diagnosis of pancreatic cancer is complex due to poor accessibility to tumour tissue. The identification of cancer-specific (somatic) mutations in peripheral blood (liquid biopsy) in genes such as KRAS, TP53, CDKN2A, and SMAD4 may lead to earlier detection and diagnosis of pancreatic cancer.
In Altum sequencing, a pancreatic cancer-specific approach has been developed to screen somatic mutations in circulating DNA of peripheral blood, generating complementary information to histology. This test can be used in follow-up liquid biopsies to quantify specific patient cancer markers, for treatment response assessment, remission monitoring, and early relapse detection.